CDK4 and neoplasm: Based on the molecular docking results, compound WXJ-202 was found to have a high binding capacity for CDK4 and CDK6. This experiment explored the possible anti-tumor effect of compound WXJ-202 on TNBC as well as its molecular mechanism, which provided a potential drug target for the treatment of TNBC.